MedTrace Logo

Fexofenadine Study On Filipino Children for The Relief of Perennial And Intermittent Allergic Rhinitis

NCT00741897 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 264

Last updated 2009-09-15

No results posted yet for this study

Summary

To determine the safety and efficacy of Fexofenadine (Telfast®) 30mg pediatric tablets on Filipino children aged 6 to 11 for the relief of symptoms associated with perennial and intermittent allergic rhinitis.

Conditions

  • Rhinitis, Allergic, Perennial

Interventions

DRUG

Fexofenadine

Fexofenadine: One 30 mg Tablet once daily for two weeks

Sponsors & Collaborators

Principal Investigators

  • Carmela Pagunsan · Sanofi

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
6 Years
Max Age
11 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2002-03-31
Primary Completion
2003-12-31

Countries

  • Philippines

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00741897 on ClinicalTrials.gov